Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

Similar articles for PubMed (Select 17090653)


Beta common receptor inactivation attenuates myeloproliferative disease in Nf1 mutant mice.

Kim A, Morgan K, Hasz DE, Wiesner SM, Lauchle JO, Geurts JL, Diers MD, Le DT, Kogan SC, Parada LF, Shannon K, Largaespada DA.

Blood. 2007 Feb 15;109(4):1687-91. Epub 2006 Nov 7.


Leukemic potential of doubly mutant Nf1 and Wv hematopoietic cells.

Ingram DA, Wenning MJ, Shannon K, Clapp DW.

Blood. 2003 Mar 1;101(5):1984-6. Epub 2002 Oct 17.


Nf1 and Gmcsf interact in myeloid leukemogenesis.

Birnbaum RA, O'Marcaigh A, Wardak Z, Zhang YY, Dranoff G, Jacks T, Clapp DW, Shannon KM.

Mol Cell. 2000 Jan;5(1):189-95.


Tie2-Cre-induced inactivation of a conditional mutant Nf1 allele in mouse results in a myeloproliferative disorder that models juvenile myelomonocytic leukemia.

Gitler AD, Kong Y, Choi JK, Zhu Y, Pear WS, Epstein JA.

Pediatr Res. 2004 Apr;55(4):581-4. Epub 2004 Jan 22.


Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder.

Le DT, Kong N, Zhu Y, Lauchle JO, Aiyigari A, Braun BS, Wang E, Kogan SC, Le Beau MM, Parada L, Shannon KM.

Blood. 2004 Jun 1;103(11):4243-50. Epub 2004 Feb 24.


Nf1 regulates hematopoietic progenitor cell growth and ras signaling in response to multiple cytokines.

Zhang YY, Vik TA, Ryder JW, Srour EF, Jacks T, Shannon K, Clapp DW.

J Exp Med. 1998 Jun 1;187(11):1893-902.


Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor.

Chan RJ, Leedy MB, Munugalavadla V, Voorhorst CS, Li Y, Yu M, Kapur R.

Blood. 2005 May 1;105(9):3737-42. Epub 2005 Jan 11.


Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.

Wiesner SM, Geurts JL, Diers MD, Bergerson RJ, Hasz DE, Morgan KJ, Largaespada DA.

Am J Hematol. 2011 Jul;86(7):579-85. doi: 10.1002/ajh.22035.


Patterns of hematopoietic lineage involvement in children with neurofibromatosis type 1 and malignant myeloid disorders.

Miles DK, Freedman MH, Stephens K, Pallavicini M, Sievers EL, Weaver M, Grunberger T, Thompson P, Shannon KM.

Blood. 1996 Dec 1;88(11):4314-20.


Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.

Chang T, Krisman K, Theobald EH, Xu J, Akutagawa J, Lauchle JO, Kogan S, Braun BS, Shannon K.

J Clin Invest. 2013 Jan;123(1):335-9. doi: 10.1172/JCI63193. Epub 2012 Dec 10.


Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis.

Chan G, Kalaitzidis D, Usenko T, Kutok JL, Yang W, Mohi MG, Neel BG.

Blood. 2009 Apr 30;113(18):4414-24. doi: 10.1182/blood-2008-10-182626. Epub 2009 Jan 29.


Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1.

Side LE, Emanuel PD, Taylor B, Franklin J, Thompson P, Castleberry RP, Shannon KM.

Blood. 1998 Jul 1;92(1):267-72.


Juvenile myelomonocytic leukemia.

Emanuel PD.

Curr Hematol Rep. 2004 May;3(3):203-9. Review.


Nf1 deficiency causes Ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia.

Largaespada DA, Brannan CI, Jenkins NA, Copeland NG.

Nat Genet. 1996 Feb;12(2):137-43.


Normal hematopoiesis and neurofibromin-deficient myeloproliferative disease require Erk.

Staser K, Park SJ, Rhodes SD, Zeng Y, He YZ, Shew MA, Gehlhausen JR, Cerabona D, Menon K, Chen S, Sun Z, Yuan J, Ingram DA, Nalepa G, Yang FC, Clapp DW.

J Clin Invest. 2013 Jan;123(1):329-34. doi: 10.1172/JCI66167. Epub 2012 Dec 10.


Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells.

Bollag G, Clapp DW, Shih S, Adler F, Zhang YY, Thompson P, Lange BJ, Freedman MH, McCormick F, Jacks T, Shannon K.

Nat Genet. 1996 Feb;12(2):144-8.


Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor is toxic to blasts from patients with juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia.

Frankel AE, Lilly M, Kreitman R, Hogge D, Beran M, Freedman MH, Emanuel PD, McLain C, Hall P, Tagge E, Berger M, Eaves C.

Blood. 1998 Dec 1;92(11):4279-86.


Genome-wide single-nucleotide polymorphism analysis in juvenile myelomonocytic leukemia identifies uniparental disomy surrounding the NF1 locus in cases associated with neurofibromatosis but not in cases with mutant RAS or PTPN11.

Flotho C, Steinemann D, Mullighan CG, Neale G, Mayer K, Kratz CP, Schlegelberger B, Downing JR, Niemeyer CM.

Oncogene. 2007 Aug 23;26(39):5816-21. Epub 2007 Mar 12.


Inhibition of juvenile myelomonocytic leukemia cell growth in vitro by farnesyltransferase inhibitors.

Emanuel PD, Snyder RC, Wiley T, Gopurala B, Castleberry RP.

Blood. 2000 Jan 15;95(2):639-45.


In vitro and in vivo effects of a farnesyltransferase inhibitor on Nf1-deficient hematopoietic cells.

Mahgoub N, Taylor BR, Gratiot M, Kohl NE, Gibbs JB, Jacks T, Shannon KM.

Blood. 1999 Oct 1;94(7):2469-76.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk